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Abstract
Background: It is well know that arterial stiffness, oxidative stress and inflammation are features
of chronic kidney disease. The arterial changes have a multitude of potential interconnected causes
including endothelial dysfunction, oxidative stress, inflammation, atherosclerosis and vascular
calcification. There is evidence that arterial stiffness becomes progressively worse as CKD
progresses. The contribution of the biochemical changes of uremic toxicity to arterial stiffness is
less clear. The aim of this study is to elucidate the vascular changes in acute kidney injury. We
hypothesise that arterial stiffness will be increased during acute kidney injury and this will return to
normal after kidney function recovers.
Methods/Design: One hundred and forty four patients with acute kidney injury defined as an
acute increase in serum creatinine to > 133 μmol/l or urea > 14.3 mmol/l or urine output < 410
ml/day will be recruited. Baseline measures of aortic pulse wave velocity, augmentation index, and
brachial and central blood pressure will be recorded along with blood measures for oxidative stress
and inflammation. Repeat measures will be taken at six and 12 months after the onset of the acute
kidney injury.
Discussion: The role and contribution of the biochemical changes to arterial stiffness in the acute
phase of kidney disease is not known. This study will primarily assess the time course changes in
pulse wave velocity from the onset of acute kidney injury and after recovery. In addition it will
assess augmentation index, central blood pressure and oxidative stress and inflammation. This may
shed light on the contribution of biochemical kidney toxins on arterial stiffness in both acute kidney
injury and chronic kidney disease.
Trial Registration: ACTRN 12609000285257
Published: 18 June 2009
BMC Nephrology 2009, 10:15 doi:10.1186/1471-2369-10-15
Received: 18 May 2009
Accepted: 18 June 2009
This article is available from: http://www.biomedcentral.com/1471-2369/10/15
© 2009 Fassett et al; licensee BioMed Central Ltd. 
This is an Open Access article distributed under the terms of the Creative Commons Attribution License (http://creativecommons.org/licenses/by/2.0), 
which permits unrestricted use, distribution, and reproduction in any medium, provided the original work is properly cited.BMC Nephrology 2009, 10:15 http://www.biomedcentral.com/1471-2369/10/15
Page 2 of 5
(page number not for citation purposes)
Background
Vascular disease, characterised by premature atherosclero-
sis and large artery stiffness, is a feature of advanced
chronic kidney disease (CKD) [1,2]. Central pulse pres-
sure, augmentation index (AIx) and aortic pulse wave
velocity (PWV) are all predictors of morbidity and mortal-
ity in patients with CKD [1,3,4]. Large artery stiffness may
also be related to the progression of CKD. The mecha-
nisms and time frames for the development of arterial
stiffness are unclear but may include traditional cardio-
vascular risk factors such as dyslipidemia and hyperten-
sion as well as non-traditional risk factors such as
oxidative stress and inflammation. Moreover, to our
knowledge no studies have assessed the relationship
between arterial stiffness in the uraemic environment of
acute kidney injury. Measuring arterial stiffness in this set-
ting would enable us to determine whether changes in
arterial stiffness occur due to the biochemical changes
associated with acute kidney injury without the interfer-
ence of factors such as chronic vascular calcification that
exist in chronic kidney disease. This may in turn help to
understand the potential for reversibility of uremic bio-
chemical effects on arterial stiffness.
Methods/Design
Study Design and Setting
This is a longitudinal observational clinical study. Patients
from the Royal Brisbane and Women's Hospital and the
Launceston General Hospital will be recruited into this
study. These hospitals service populations of approxi-
mately 1.2 million and 250,000 respectively.
Ethical Considerations
The Tasmanian Statewide Scientific and Ethics Commit-
tees and the Human Research and Ethics Committee of
the Royal Brisbane and Women's Hospital have approved
this study.
Identification of Eligible Patients
Study population
One hundred and forty four patients with acute kidney
injury and 45 matched controls.
Acute kidney injury participants will be recruited from
two settings at each hospital.
1. The Intensive care unit: The distinguishing features of
intensive care research are the requirements to recruit and
obtain informed consent rapidly when it may be difficult
to communicate with the patient. As the patient require-
ments for this study are minimal and non-invasive it is
not expected that these requirements will be problematic.
All attempts will be made to gain informed written con-
sent directly from the patient. The patients will be
approached by one of the investigators who will explain
the study, provide them with the information sheet and
request they consider entering the study and therefore
sign the consent form. If patients are unable to provide
written informed consent themselves (e.g. they are uncon-
scious or too unwell) the next of kin will be approached
by one of the investigators who will explain the study,
provide them with the information sheet and request that
they consider the patient enters the study and sign the
consent form on their behalf.
2. The Renal medicine service: This will include the renal
inpatients and referrals from General Internal Medicine,
Surgery and other departments in the Royal Brisbane and
Women's Hospital. For these patients the recruitment will
be based on the standard informed consent process as
described above for the conscious intensive care unit
patient.
Accrual time
Two years
Eligibility
Inclusion criteria: Male and female patients > 18 years of
age presenting to the Royal Brisbane and Women's Hospi-
tal and the Launceston General Hospital with acute kid-
ney injury but not having started dialysis or continuous
venovenous hemofiltration will be eligible for recruit-
ment (Figure 1). Acute kidney injury will be defined as the
presence of a serum creatinine > 133 μmol/l or urea > 14.3
mmol/l or urine output < 410 ml/day [5,6].
Study patient flow Figure 1
Study patient flow.
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Exclusion criteria: Patients receiving vasoactive drugs such
as inotropic agents or on dialysis or continuous veno-
venous hemofiltration will be excluded. In addition, any
patients with a condition the treating doctor deems to pre-
clude the patient participating based on safety concerns
will be excluded. Patients planned for palliative care,
unwilling to comply with trial requirements, or whose life
expectancy is severely limited (< six months) due to pre-
existing malignancy or other disease will be excluded.
Finally, patients that are pregnant or have a planned preg-
nancy will also be excluded.
Primary Objectives and Primary Outcome Measures
Aims and hypotheses
Primary aim
To determine the effects of acute kidney injury on arterial
stiffness
Hypothesis 1
Patients with acute kidney injury will have increased arte-
rial stiffness compared to matched controls.
Hypothesis 2
Patients who recover kidney function following acute kid-
ney injury will have a concomitant reduction in arterial
stiffness.
Primary outcome measure
Arterial stiffness
Carotid to femoral PWV will be derived by electrocardiog-
raphy-gated sequential applanation tonometry (SPT-301
Mikro-Tip, Millar Instruments, Houston, Texas) using the
foot-to-foot method (SphymoCor™ 7.01 AtCor, Sydney,
Australia) [7]. Testing will be performed in a temperature-
controlled room and after 5–10 minutes rest with the sub-
ject in the supine position prior to the first measure. Two
measures will be averaged for the estimation of aortic
PWV. Aortic stiffness (carotid to femoral PWV) will be
derived by electrocardiography-gated sequential applana-
tion tonometry using the foot-to-foot method (Sphygmo-
Cor 7.01 AtCor, Sydney, Australia) as previously described
[7]. Briefly, three ECG electrodes are placed on the
patient's chest and they are required to lie quietly for 15
minutes. Brachial blood pressure is measured and then
the tonometer is applied sequentially over the radial,
carotid and femoral arteries. The procedure takes around
15 minutes, but this may vary depending on patient mor-
phology.
Secondary Aim and Secondary Outcome Measures
Secondary Aim
To determine the associations between oxidative stress
and inflammation with changes in arterial stiffness and
central blood pressure in patients with acute kidney
injury.
Hypothesis
There will be significant relationships between oxidative
stress and inflammation and changes in arterial stiffness
and central blood pressure in patients with acute kidney
injury.
Secondary outcome measures
Oxidative Stress
The outcome measure for oxidative stress will be plasma
isoprostanes measured using gas chromatography mass
spectrometry [8]. In addition, plasma protein carbonyls,
total antioxidant capacity and antioxidant enzyme activi-
ties will also be measured to further assess oxidative stress
and antioxidant status.
Inflammation
The outcome measure for inflammation will be pentraxin
3 measured using an ELISA assay [9]. In addition, inter-
leukin (IL)-6, IL-8, IL-10, high sensitivity C reactive pro-
tein and tumour necrosis factor-alpha will be measured as
further markers of inflammation.
Central blood pressure and augmentation index (AIx)
The SphygmoCor device will be used to determine central
blood pressure and AIx as additional markers of arterial
stiffness. A central (ascending aortic) pressure waveform
will be derived by radial tonometry as previously
described [7]. This method involves placing a tonometer
over the radial artery and using a generalised transfer func-
tion to transform the radial pressure waveform. Central
pulse pressure will be recorded as an estimate of afterload
and AIx as a composite measure of systemic arterial stiff-
ness and arterial wave reflection. The central waveform
will be calibrated by the average of two measures of bra-
chial blood pressure using a semi-automated device (UA-
767, A&D, Saitama, Japan) after five minutes of supine
rest.
Additional data and routine measures
Routine measures including full blood count, electrolytes,
coagulation profile, liver function test and lipid profile
will be carried out at the Hospitals' Pathology Laborato-
ries. Other data collected at the time will include demo-
graphic details, medical history and medication profile.
Sample handling and storage
Upon collection, blood samples will be placed on ice and
then centrifuged (500 g) at 4°C for five minutes. One ml
aliquots of plasma will be stored in eppendorf tubes
immediately at -80°C for future biochemical analyses of
oxidative stress and inflammation.
Baseline testing
After patients provide informed consent they will undergo
baseline testing to measure resting peripheral and centralBMC Nephrology 2009, 10:15 http://www.biomedcentral.com/1471-2369/10/15
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blood pressure, arterial stiffness and have blood taken for
standard biochemistry and measures of oxidative stress
and inflammation. Control data will be obtained from a
database of one of the authors that contains arterial stiff-
ness measures on healthy individuals with normal kidney
function. Subjects from this database will be selected to
match with patients included in the analyses.
Visits two and three
All measures taken at baseline will be repeated at six and
twelve months after the onset of the acute kidney injury.
Recovery of kidney function
This will be defined as return of kidney function to nor-
mal (eGFR > 60 ml/min/1.73 m2) or, where data is avail-
able, a return to the level of kidney function within 5%
assessed by eGFR present within three months prior to the
acute kidney injury.
Withdrawal from Study
If requested, subjects will be withdrawn from the study
without prejudice, as documented and explained at the
time of consenting.
Statistical considerations
Sample size calculation
Sample sizes of 144 acute kidney injury patients and 45
matched controls have been determined as follows. The
primary outcome measure is aortic PWV. To our knowl-
edge, there is no published aortic PWV data available for
acute kidney injury patients. We therefore used haemodi-
alysis patient aortic PWV data from one of our other inves-
tigations, the PEDAL study[10]. We found that the aortic
PWV of dialysis patients was 9.4 +/- 1.9 m/sec. Previous
work from Blacher et al reported that for each 1 m/sec
increase in aortic PWV there is a 34% increase in both car-
diovascular and total mortality [11]. We assume that this
increase is clinically relevant. Therefore in order to detect
a 1 m/sec difference in PWV compared to controls
(hypothesis 1) or 1 m/sec change in aortic PWV in the
patients (hypothesis 2) 45 patients will be required (beta
1-0.8 = 0.20, alpha = 0.05 using a two tailed paired t test).
This assumes the initial aortic PWV will be 9.4 +/- 1.9 m/
sec and if the hypotheses are supported the aortic PWV in
controls and on restoration of kidney function will be 8.4
+/- 1.9 m/sec. However allowing for 1) a high loss to fol-
low-up rate (50%) because of the mortality associated
with acute kidney injury, particularly in ICU, and 2) the
expected number of patients who will recover kidney
function after 12 months (60%) then at least 144 patients
will need to be recruited to achieve the 45 patients
required.
Statistical analyses
General linear modelling will be used to test the hypothe-
ses. Bi-variate and multivariate techniques will be used to
assess the secondary aims of the relative independent
effects of variables on the outcomes measures. Signifi-
cance will be assumed if P < 0.05.
Discussion
The objective of this study is to assess whether the bio-
chemical changes seen in acute kidney injury can affect
arterial stiffness. Although arterial stiffness is a feature of
vascular dysfunction in chronic kidney disease it is not
clear how much, if at all the biochemical abnormalities
seen in the circulation account for such changes. In addi-
tion, the study will assess augmentation index, central
blood pressure and oxidative stress and inflammation.
Data from this study may lead to a better understanding
of the vascular dysfunction seen in kidney disease.
Competing interests
The authors declare that they have no competing interests.
Authors' contributions
RGF and JSC designed the study and wrote the protocol.
JG provided advice and input and will be involved with
the intensive care component of the study. VD and HH
provided advice and input and will be involved with the
renal medicine department component of the study. J-S G
will perform arterial stiffness measures and contributed to
manuscript review. JS provide advice and input into the
arterial stiffness measures and reviewed the manuscript.
All authors read and approved the final manuscript.
Acknowledgements
We would like to thank Lisa Anderson, Ritza Driver, Marianne Smith, David 
Holland, Kirsten Koh, Colleen Morgan and Cheryl Fourie for their assist-
ance in setting up the study. Funding for the study is being kindly provided 
from a Strategic Research Grant from the Royal Brisbane and Women's 
Hospital Research Foundation and from a Mayne Bequest Fund Grant from 
The University of Queensland.
References
1. Blacher J, Guerin AP, Pannier B, Marchais SJ, Safar ME, London GM:
Impact of aortic stiffness on survival in end-stage renal dis-
ease.  Circulation 1999, 99(18):2434-2439.
2. DeLoach SS, Townsend RR: Vascular stiffness: its measurement
and significance for epidemiologic and outcome studies.  Clin
J Am Soc Nephrol 2008, 3(1):184-192.
3. London GM, Blacher J, Pannier B, Guerin AP, Marchais SJ, Safar ME:
Arterial wave reflections and survival in end-stage renal fail-
ure.  Hypertension 2001, 38(3):434-438.
4. Safar ME, Blacher J, Pannier B, Guerin AP, Marchais SJ, Guyonvarc'h
PM, London GM: Central pulse pressure and mortality in end-
stage renal disease.  Hypertension 2002, 39(3):735-738.
5. Knaus WA, Zimmerman JE, Wagner DP, Draper EA, Lawrence DE:
APACHE-acute physiology and chronic health evaluation: a
physiologically based classification system.  Crit Care Med 1981,
9(8):591-597.
6. Mehta RL, Pascual MT, Soroko S, Chertow GM: Diuretics, mortal-
ity, and nonrecovery of renal function in acute renal failure.
JAMA 2002, 288(20):2547-2553.Publish with BioMed Central    and   every 
scientist can read your work free of charge
"BioMed Central will be the most significant development for 
disseminating the results of biomedical research in our lifetime."
Sir Paul Nurse, Cancer Research UK
Your research papers will be:
available free of charge to the entire biomedical community
peer reviewed and published  immediately upon acceptance
cited in PubMed and archived on PubMed Central 
yours — you keep the copyright
Submit your manuscript here:
http://www.biomedcentral.com/info/publishing_adv.asp
BioMedcentral
BMC Nephrology 2009, 10:15 http://www.biomedcentral.com/1471-2369/10/15
Page 5 of 5
(page number not for citation purposes)
7. Wilkinson IB, Fuchs SA, Jansen IM, Spratt JC, Murray GD, Cockcroft
JR, Webb DJ: Reproducibility of pulse wave velocity and aug-
mentation index measured by pulse wave analysis.  J Hypertens
1998, 16(12 Pt 2):2079-2084.
8. Mori TA, Croft KD, Puddey IB, Beilin LJ: An improved method for
the measurement of urinary and plasma F2-isoprostanes
using gas chromatography-mass spectrometry.  Anal Biochem
1999, 268(1):117-125.
9. Rolph MS, Zimmer S, Bottazzi B, Garlanda C, Mantovani A, Hansson
GK:  Production of the long pentraxin PTX3 in advanced
atherosclerotic plaques.  Arterioscler Thromb Vasc Biol 2002,
22(5):e10-14.
10. Koh KP, Fassett RG, Sharman JE, Coombes JS, Williams AD: Intradi-
alytic versus home based exercise training in hemodialysis
patients: a randomised controlled trial.  BMC Nephrol 2009,
10:2.
11. Blacher J, Safar ME, Guerin AP, Pannier B, Marchais SJ, London GM:
Aortic pulse wave velocity index and mortality in end-stage
renal disease.  Kidney Int 2003, 63(5):1852-1860.
Pre-publication history
The pre-publication history for this paper can be accessed
here:
http://www.biomedcentral.com/1471-2369/10/15/pre
pub